Lymphoma

>

Latest News

FDA Grants Fast Track Designation to Azer-cel in R/R DLBCL
FDA Grants Fast Track Designation to Azer-cel in R/R DLBCL

March 20th 2025

Azer-cel elicited strong and durable responses in patients with heavily pretreated relapsed/refractory DLBCL in a phase 1b trial.

EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma
EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma

March 14th 2025

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

March 7th 2025

AUTO4 CAR T cells plus fludarabine and cyclophosphamide was well tolerated in patients with relapsed or refractory peripheral T cell lymphoma.
TRBC1-Directed CAR T-Cell Therapy Exhibits Preliminary Efficacy in PTCL

March 1st 2025

Data from the phase 3 STARGLO study support the CHMP’s recommendation for approving glofitamab plus gemcitabine/oxaliplatin in relapsed/refractory DLBCL.
CHMP Recommends EU Approval for Glofitamab Combination in R/R DLBCL

February 28th 2025

More News